| 摘要 |
The disclosure relates to novel 11-epi- .DELTA.4-prostaglandin analogs in the .omega.-aryloxy-series, for example 16-(3-chlorophenoxy)-9.alpha.,11.beta.,15.alpha.-trihydroxy-17,18,19,20-tetranor-4-cis,13-trans-prostadienoic acid, which possess high lutolytic activity in animals, processes for their manufacture and pharmaceutical and veterinary compositions containing them. |
